42 CFR Part 2: Why Substance Abuse Treatment Data Gets Extra Protection

The Federal Regulation Most Healthcare Marketers Have Never Read

Title 42 of the Code of Federal Regulations, Part 2 has governed the confidentiality of substance use disorder (SUD) treatment records since 1975. It was enacted before HIPAA existed, before electronic health records existed, and before a single tracking pixel had ever fired on a healthcare website. Its purpose was specific and urgent: people struggling with addiction were avoiding treatment because they feared their records would be used against them in criminal proceedings, employment decisions, or insurance denials.

Nearly fifty years later, that fear has found new justification. The same marketing technologies that have generated $193M+ in enforcement actions across the healthcare industry now pose a unique threat to substance abuse treatment providers. Because Part 2 imposes requirements that go beyond HIPAA, organizations treating SUD patients face a higher compliance bar that most marketing teams do not realize exists.

What Part 2 Actually Says in Plain English

HIPAA allows covered entities to share protected health information for treatment, payment, and healthcare operations without individual authorization in many circumstances. Part 2 does not.

Under 42 CFR Part 2, records from federally assisted substance use disorder programs cannot be disclosed without the patient's specific written consent, with limited exceptions. The regulation applies to any program that receives federal funding (including Medicare or Medicaid reimbursement) and holds itself out as providing SUD diagnosis, treatment, or referral.

The consent requirements are stricter than a standard HIPAA authorization. A valid Part 2 consent must name the specific person or entity receiving the information, describe the type and amount of information to be disclosed, state the purpose of the disclosure, include an expiration date or event, and inform the patient of their right to revoke consent. A blanket consent form that says "I agree to share my data with our technology partners" does not meet Part 2 standards.

The regulation also includes a prohibition on re-disclosure. When a Part 2 program shares patient information with a recipient, that recipient cannot re-disclose the information to anyone else without a new, separate patient consent. This creates a chain-of-custody requirement that has no parallel in standard HIPAA compliance.

The 2024 Final Rule: Part 2 Aligns with HIPAA but Keeps Its Teeth

In February 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) finalized a major update to Part 2, implementing changes required by the CARES Act of 2020. The final rule aligned Part 2 more closely with HIPAA by allowing a single consent for all future uses related to treatment, payment, and healthcare operations.

This change was significant. Before the 2024 update, SUD programs often needed separate patient consent for each specific disclosure, creating administrative burden that some argued interfered with care coordination.

But the alignment did not eliminate Part 2's additional protections. The regulation still prohibits using SUD records in criminal, civil, or administrative proceedings against the patient without a court order or patient consent. The re-disclosure prohibition remains in effect, meaning downstream recipients still cannot share Part 2 records freely. And critically for marketing teams, the regulation still requires that any use of SUD records beyond treatment, payment, and operations requires specific patient authorization.

Marketing is not treatment. Marketing is not payment. Marketing is not healthcare operations. SUD treatment records cannot be used for marketing purposes under Part 2 without explicit, compliant patient consent.

Where Marketing Technology Collides with Part 2

Consider what happens when a substance abuse treatment center installs standard marketing tools on its website. A visitor browses pages about opioid treatment programs, alcohol detox services, or medication-assisted treatment. Analytics platforms log these page visits tied to IP addresses, device IDs, and browser fingerprints. Tracking pixels transmit that browsing behavior to advertising platforms. Retargeting campaigns then serve ads to those visitors across the internet, signaling to anyone who sees their screen that they were researching addiction treatment.

This is not a hypothetical scenario. It is the exact pattern that has driven enforcement across healthcare.

Monument (FTC advertising ban, 2024). Monument, an alcohol addiction treatment platform, disclosed data of up to 84,000 users to ad platforms via tracking pixels. Their custom pixel events had descriptive titles like "Paid: Weekly Therapy" and "Paid: Med Management," revealing specific services alongside email addresses and IP addresses. The FTC banned Monument from sharing health data for advertising. Source

Monument's case is directly relevant to Part 2 because it involved substance abuse treatment data flowing to advertising platforms through routine marketing technology. The descriptive event names functioned as treatment records, connecting identifiable individuals to specific addiction services.

BetterHelp ($7.8M FTC, 2023). BetterHelp shared email addresses, IP addresses, and mental health intake questionnaire responses with Facebook, Snapchat, Criteo, and Pinterest via tracking pixels. The company used the fact that users had been in therapy to build Facebook lookalike audiences. Source

While BetterHelp was a mental health platform rather than a Part 2 program, the enforcement illustrates how intake questionnaire data and treatment status become PHI when transmitted to third parties. For a Part 2 covered program, this same data flow would violate both HIPAA and Part 2's stricter consent requirements.

The Re-Disclosure Problem for Analytics Vendors

Part 2's re-disclosure prohibition creates a compliance challenge that has no equivalent in standard HIPAA. When a Part 2 program shares data with a business associate, that associate cannot share the data downstream without new patient consent.

In practice, this means a treatment center cannot send patient data to an analytics platform that then shares it with advertising networks. It means a client-side tracking pixel that sends data from the patient's browser to Google or Meta violates the re-disclosure rule by design. The browser is the re-disclosure mechanism: it takes data from the treatment center's website and transmits it to third-party servers without any consent check.

Server-side architecture addresses this structurally. When data flows from the treatment center's server to a compliant analytics platform, and that platform holds a BAA with Part 2 provisions, the data never reaches a third-party endpoint through the browser. The re-disclosure chain is broken at the infrastructure level rather than relying on policy alone.

Building a Compliant Marketing Stack for SUD Programs

SUD treatment providers need to market their services. People struggling with addiction need to find treatment. The goal is not to eliminate marketing but to build it on infrastructure that respects Part 2's requirements.

Consent must be granular and verifiable. Part 2 consent for marketing purposes must be separate from treatment consent. It must specify what data will be used, who will receive it, and for what purpose. Consent-gated data flows, where information only moves to marketing systems after server-side consent verification, are the technical implementation of this legal requirement.

Analytics must stay first-party. Client-side analytics tools that send data to third-party servers create automatic re-disclosure violations for Part 2 programs. First-party analytics infrastructure, where data collection happens on your domain through server-set mechanisms, keeps treatment-related browsing data within your controlled environment.

Ongoing monitoring catches drift. A web scanner that continuously audits your site's tracking surface can detect when a new script, plugin, or tag is introduced that might violate Part 2. Marketing teams add tools. Plugins update. Without continuous monitoring, a compliant setup today can become a violation next quarter without anyone noticing.

BAAs must reference Part 2 specifically. A standard HIPAA BAA may not address Part 2's re-disclosure prohibition or its specific consent requirements. SUD treatment providers should confirm that any business associate agreement with technology vendors explicitly acknowledges Part 2 obligations.

FAQ

Does 42 CFR Part 2 apply to all healthcare organizations or only SUD programs?

Part 2 applies specifically to federally assisted programs that hold themselves out as providing substance use disorder diagnosis, treatment, or referral for treatment. "Federally assisted" includes programs that receive any federal funding, participate in Medicare or Medicaid, or have tax-exempt status. A general hospital that operates a substance abuse treatment unit is subject to Part 2 for that unit's records, even if the rest of the hospital is governed only by HIPAA.

Can SUD treatment centers use Google Analytics or Meta Pixel on their websites?

Client-side tracking tools like Google Analytics and Meta Pixel transmit browsing data through the visitor's browser to third-party servers. For a Part 2 program, this creates a re-disclosure violation because the patient's interaction with SUD-related content is being shared with parties who lack patient consent. Server-side analytics that keep data within first-party infrastructure are the compliant alternative.

How does the 2024 final rule change marketing for SUD providers?

The 2024 final rule allows a single patient consent for treatment, payment, and healthcare operations, reducing administrative burden. However, marketing is not included in those categories. SUD providers still need specific, compliant patient consent before using any treatment records for marketing purposes. The consent must meet Part 2's requirements, which are more detailed than a standard HIPAA authorization.

What is the difference between Part 2 consent and HIPAA authorization?

Part 2 consent requires more specificity than HIPAA authorization. It must name the exact recipient of the information, describe the specific data being shared, state the purpose, and include an expiration date. HIPAA authorization is also detailed, but Part 2 adds the re-disclosure prohibition: the recipient of Part 2 data cannot share it further without a new patient consent. This layered protection reflects the stigma and legal risks historically associated with substance abuse records.

Does Part 2 apply to non-clinical website pages like blog posts about addiction recovery?

Part 2 protects records created by covered SUD programs, not general educational content. However, if your website combines educational content with treatment program information, and analytics tools track user behavior across both, the browsing data can connect identifiable visitors to your SUD program. A visitor who reads a blog post about opioid recovery and then views your intake form page has generated data that could implicate Part 2 protections, especially if that data is transmitted to third parties.

Substance abuse treatment marketing sits at the intersection of healthcare's broadest compliance requirements and some of its strictest privacy protections. If your organization provides SUD treatment and uses digital marketing, Ours Privacy offers the server-side infrastructure and consent-gated data flows that Part 2 requires.

Related reading:

• What Is PHI? A Healthcare Marketer's Guide

• Cookie Consent vs HIPAA Authorization

• Server-Side vs Client-Side Tracking

• HIPAA-Compliant Tools